A recent study from the Cleveland Clinic, involving nearly 8,000 participants, reveals that discontinuing medications like semaglutide and tirzepatide does not necessarily lead to significant weight regain in practical scenarios. Many patients tend to either resume their treatment later or explore alternative weight management strategies, which may help mitigate weight gain.
This extensive real-world analysis, one of the largest to date focusing on the long-term effects of ceasing GLP-1 therapies, found that a noteworthy proportion of patients managed to maintain their weight stability over a year. This success was often attributed to alternative treatments and structured lifestyle support.
Understanding Real-World Outcomes
Published in the journal Diabetes, Obesity and Metabolism, these findings provide a fresh perspective compared to earlier randomized clinical trials. Those trials indicated that patients who stopped using semaglutide (known as Ozempic or Wegovy) and tirzepatide (marketed as Mounjaro or Zepbound) typically regained over half of the weight they had lost within a year.
The new research suggests that real-world outcomes may vary, as patients often have the flexibility to adjust their treatment plans more readily.
Hamlet Gasoyan, DS, Ph.D., MPH, a researcher at the Cleveland Clinic's Center for Value-Based Care Research, spearheaded the study. "Our data indicate that many patients who discontinue semaglutide or tirzepatide either restart their medication or transition to another obesity treatment, which likely explains their reduced weight regain compared to those in randomized trials," Dr. Gasoyan noted.
Study Overview and Patient Insights
This retrospective cohort study tracked 7,938 adults with overweight or obesity across Ohio and Florida. Participants initiated treatment with injectable semaglutide or tirzepatide for obesity or type 2 diabetes and subsequently stopped the medication within three to twelve months. Researchers monitored the treatments pursued afterward and the changes in weight over time.
While most participants experienced significant weight loss, individual results varied:
- Obesity patients lost an average of 8.4% of body weight before discontinuation and regained about 0.5% after one year.
- Type 2 diabetes patients lost an average of 4.4% before stopping and lost an additional 1.3% over the next year.
- Among obesity patients, 55% regained weight post-discontinuation, while 45% either maintained or continued to lose weight.
- In the diabetes cohort, 44% gained weight, whereas 56% maintained or lost weight.
Reasons for Discontinuation and Subsequent Actions
Previous research identified two primary reasons for stopping these medications: cost or lack of insurance coverage, and side effects, with financial barriers being the most prevalent.
Patients using the drugs for type 2 diabetes were more likely to resume treatment compared to those using them for obesity, likely due to more consistent insurance coverage for diabetes medications.
Within a year of halting their initial GLP-1 medication, many patients sought other weight management options:
- 27% switched to another medication, including older obesity drugs or alternating between semaglutide and tirzepatide.
- 20% resumed their original medication.
- 14% continued with lifestyle-focused care from professionals like dietitians or exercise specialists.
- Less than 1% opted for metabolic and bariatric surgery.
Importance of Ongoing Support
The study underscores the necessity of sustained, personalized care for individuals managing obesity, even after stopping medication. "Many patients remain committed to their obesity treatment journey, even if they need to discontinue their initial medication," Dr. Gasoyan emphasized. "Our future research will explore the comparative effectiveness of alternative obesity treatment options for those who stop semaglutide or tirzepatide, aiding patients and clinicians in making informed choices."
